-
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization forresearch and treatment of cancer multicenter trialBignazoli, Laura ...BACKGROUND. The potential cardiotoxicy of the doxorubicin-paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by ... small single institution Phase II studies. METHODS. In a large multicenter Phase III trial, 275 anthracycline naive metastatic breast carcinoma patients were randomized to receive either doxorubicin (60 mg/m2) followed 30 minutes later by paclitaxel (175 mg/ m2 3-hour infusion; AT) or a standard doxorubicin-cyclophosphamide regimen (AC; 60/600 mg/m2). Both treatments were given once every 3 weeks for a maximum of six cycles. Close cardiac monitoring was implemented in the study design. RESULTS. Congestive heart failure (CHF) occurred in three patients in the AT arm and in one patient in the AC arm (P = 0.62). Decreases in left ventricularejection fraction to below the limit of normal were documented in 33% AT and 19% AC patients and were not predictive of CHF development. CONCLUSIONS. AT is devoid of excessive cardiac risk among metastatic breast carcinoma patients, when the maximum planned cumulative dose of doxorubicin does not exceed-360 mg/m2.Source: Cancer. - ISSN 0008-543X (Letn. 97, št. 1, 2003, str. 40-45)Type of material - article, component partPublish date - 2003Language - englishCOBISS.SI-ID - 16454105
Author
Bignazoli, Laura |
Čufer, Tanja, 1955- |
Bruning, Peter |
Coleman, Robert |
Duchateau, Luc |
Rapoport, Bernard |
Nooij, Marianne |
Delhaye, Francois |
Miles, D. |
Sulkes, Aaron
Topics
Breast Neoplasms |
Drug Therapy |
Pathology |
Doxorubicin |
Adverse Effects |
Paclitaxel |
Adverse Effects |
Adenocarcinoma |
Drug Therapy |
Secondary |
Cyclophosphamide |
Administration And Dosage |
Adverse Effects |
Heart Failure, Congestive |
Neoplasm Metastasis |
Multicenter Studies |
Antineoplastic Agents, Combined |
Adverse Effects |
Disease Progression |
Disease-Free Survival |
Follow-Up Studies |
Heart |
Drug Effects |
Risk Factors |
Survival Analysis |
Treatment Outcome |
Adenokarcinom |
Ciklofosfamid |
Dojka, novotvorbe |
Doksorubicin |
Paklitaksel |
Antineoplastiki sestavljeni |
Bolezen, napredovanje |
Brez bolezni, preživetje |
Dejavniki tveganja |
Novotvorba, metastaza |
Policentrične študije |
Preživetje, analiza |
Sledilne študije |
Srce |
Srce, odpoved kongestivna |
Zdravljenje, izid
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Bignazoli, Laura | ![]() |
Čufer, Tanja, 1955- | 12179 |
Bruning, Peter | ![]() |
Coleman, Robert | ![]() |
Duchateau, Luc | ![]() |
Rapoport, Bernard | ![]() |
Nooij, Marianne | ![]() |
Delhaye, Francois | ![]() |
Miles, D. | ![]() |
Sulkes, Aaron | ![]() |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.